Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 31-40 of 110 (Search time: 0.016 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2010The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cellsEngler, J.; Frede, A.; Saunders, V.; Zannettino, A.; White, D.; Hughes, T.
2010Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 ActivityEngler, J.; Frede, A.; Saunders, V.; Zannettino, A.; Hughes, T.; White, D.
2011Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathwaysTang, C.; Schafranek, L.; Watkins, D.; Parker, W.; Moore, S.; Prime, J.; White, D.; Hughes, T.
2012Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib responseWhite, D.; Hughes, T.
2013Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagySchafranek, L.; Leclercq, T.; White, D.; Hughes, T.
2017Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cellsWang, J.; Lu, L.; Kok, C.; Saunders, V.; Goyne, J.; Dang, P.; Leclercq, T.; Hughes, T.; White, D.
2017A method for next-generation sequencing of paired diagnostic and remission Samples to detect mitochondrial DNA mutations associated with leukemiaPagani, I.; Kok, C.; Saunders, V.; Van der Hoek, M.; Heatley, S.; Schwarer, A.; Hahn, C.; Hughes, T.; White, D.; Ross, D.
2012Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cellsWang, J.; Hughes, T.; Kok, C.; Saunders, V.; Frede, A.; Groot Obbink, K.; Osborn, M.; Somogyi, A.; D'Andrea, R.; White, D.
2018Molecular monitoring in CML: How deep? How often? How should it influence therapy?Shanmuganathan, N.; Hughes, T.
2018Molecular monitoring in CML: how deep? How often? How should it influence therapy?Shanmuganathan, N.; Hughes, T.